Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston; Andre Goy; Maria Alma Rodriguez; Christopher Ehmann; Paul Hamlin; John Radford; Catherine Thieblemont; Cheolwon Suh; John Sweetenham; Ying Jiang; Sharon T. Sullivan; Erik R. Vandendries; Christian Gisselbrecht

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, Andre Goy, Maria Alma Rodriguez, Christopher Ehmann, Paul Hamlin, John Radford, Catherine Thieblemont, Cheolwon Suh, John Sweetenham, Ying Jiang, Sharon T. Sullivan, Erik R. Vandendries, Christian Gisselbrecht

Manchester Institute of Education

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Pages (from-to)	1169-1170
Number of pages	2
Journal	Blood
Volume	118
Issue number	21
Publication status	Published - 18 Nov 2011

Cite this

Wagner-Johnston, N., Goy, A., Rodriguez, M. A., Ehmann, C., Hamlin, P., Radford, J., Thieblemont, C., Suh, C., Sweetenham, J., Jiang, Y., Sullivan, S. T., Vandendries, E. R., & Gisselbrecht, C. (2011). Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. Blood, 118(21), 1169-1170.

@article{5661fcac6a29432abd8e08568ffbcdea,

title = "Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy",

author = "Nina Wagner-Johnston and Andre Goy and Rodriguez, {Maria Alma} and Christopher Ehmann and Paul Hamlin and John Radford and Catherine Thieblemont and Cheolwon Suh and John Sweetenham and Ying Jiang and Sullivan, {Sharon T.} and Vandendries, {Erik R.} and Christian Gisselbrecht",

year = "2011",

month = nov,

day = "18",

language = "Undefined",

volume = "118",

pages = "1169--1170",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "21",

}

Wagner-Johnston, N, Goy, A, Rodriguez, MA, Ehmann, C, Hamlin, P, Radford, J, Thieblemont, C, Suh, C, Sweetenham, J, Jiang, Y, Sullivan, ST, Vandendries, ER & Gisselbrecht, C 2011, 'Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy', Blood, vol. 118, no. 21, pp. 1169-1170.

TY - JOUR

T1 - Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients

T2 - Safety and Efficacy

AU - Wagner-Johnston, Nina

AU - Goy, Andre

AU - Rodriguez, Maria Alma

AU - Ehmann, Christopher

AU - Hamlin, Paul

AU - Radford, John

AU - Thieblemont, Catherine

AU - Suh, Cheolwon

AU - Sweetenham, John

AU - Jiang, Ying

AU - Sullivan, Sharon T.

AU - Vandendries, Erik R.

AU - Gisselbrecht, Christian

PY - 2011/11/18

Y1 - 2011/11/18

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000299597104069&KeyUID=WOS:000299597104069

M3 - Meeting Abstract

SN - 0006-4971

VL - 118

SP - 1169

EP - 1170

JO - Blood

JF - Blood

IS - 21

ER -

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin plus Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Other files and links

Cite this